Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025)
Halozyme Therapeutics (HALO) posted quarterly Long-Term Deferred Tax of $20.2 million for Q2 2025, up 289.36% quarter-over-quarter from $5.2 million in Q1 2025.
Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Long-Term Deferred Tax for 5 consecutive years, with $20.2 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Long-Term Deferred Tax changed N/A year-over-year to $20.2 million; the TTM figure through Jun 2025 stood at $20.2 million (changed N/A YoY), while the FY2024 annual figure was $3.9 million, down 12.11% from the prior year.
- Long-Term Deferred Tax climbed to $20.2 million in Q2 2025 per HALO's latest filing, from $5.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $155.4 million in Q4 2021 and bottomed at $616000.0 in Q1 2024.
- Historically, Long-Term Deferred Tax has averaged $49.3 million across 5 years, with a median of $22.1 million in 2023.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax tumbled 98.27% — and 2025, when it soared 742.53%.
- Halozyme Therapeutics' Long-Term Deferred Tax stood at $155.4 million in 2021, then plunged by 71.42% to $44.4 million in 2022, then sank by 90.13% to $4.4 million in 2023, then decreased by 12.11% to $3.9 million in 2024, then surged by 424.2% to $20.2 million in 2025.
- Business Quant data shows HALO's Long-Term Deferred Tax at $20.2 million in Q2 2025, $5.2 million in Q1 2025, and $3.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 20.21 Mn |
| Mar 31, 2025 | 5.19 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Mar 31, 2024 | 616,000.00 |
| Dec 31, 2023 | 4.39 Mn |
| Sep 30, 2023 | 13.41 Mn |
| Jun 30, 2023 | 23.92 Mn |
| Mar 31, 2023 | 35.68 Mn |
| Dec 31, 2022 | 44.43 Mn |
| Mar 31, 2022 | 142.51 Mn |
| Dec 31, 2021 | 155.43 Mn |
| Sep 30, 2021 | 142.48 Mn |